Table 4.
Survey Questions and Responses
| Question Number | Survey Question | Answer Choices | % of Responses (Number of Responses) | Total Number of Responses |
|---|---|---|---|---|
| 1 | Have you ever used bevacizumab for the management of glioblastoma? | Yes | 100% (62) | 62 |
| No | 0% (0) | |||
| 2 | In what setting do you use bevacizumab in patients with glioblastoma? (multiple answers were allowed) | Newly diagnosed glioblastoma as a standard of care | 3.2% (2) | 60 |
| Newly diagnosed glioblastoma for the control of edema | 61.7% (37) | |||
| Recurrent glioblastoma as a standard of care | 60% (36) | |||
| Recurrent glioblastoma for the control of edema | 85% (51) | |||
| Recurrent glioblastoma when there are no other treatment options | 68.3% (41) | |||
| 3 | Why do you use bevacizumab in patients with glioblastoma? | As an antineoplastic agent | 1.7% (1) | 62 |
| As a steroid sparing agent/for control of edema | 26.7% (16) | |||
| Both | 71.7% (43) | |||
| None | 0% (0) | |||
| 4 | What is your opinion about the clinical benefit of bevacizumab in glioblastoma patients? | Improves survival | 0% (0) | 58 |
| Improves symptoms | 67.2% (39) | |||
| Both | 29.3% (17) | |||
| None | 3.4% (2) | |||
| 5 | What percentage of your patients with newly diagnosed glioblastoma gets treated with bevacizumab? | <5% | 78.3% (47) | 60 |
| 5% to 10% | 15% (9) | |||
| 10% to 25% | 5% (3) | |||
| >25% | 1.7% (1) | |||
| 6 | What percentage of your patients with recurrent glioblastoma gets treated with bevacizumab at some point in their disease course? | <5% | 0% (0) | 58 |
| 5% to 10% | 8.6% (5) | |||
| 10% to 25% | 6.9% (4) | |||
| >25% | 84.5% (49) | |||
| 7 | What dose of bevacizumab do you most commonly use in patients with glioblastoma? | 10 mg/kg | 90% (54) | 60 |
| 7.5 mg/kg | 5% (3) | |||
| 5 mg/kg | 5% (3) | |||
| 8 | What frequency of bevacizumab do you most commonly use in patients with glioblastoma? | Every 2 weeks | 85% (51) | 60 |
| Every 3 weeks | 11.7% (7) | |||
| Every 4 weeks | 3.3% (2) | |||
| 9 | In which combination do you most commonly use bevacizumab for recurrent glioblastoma? | I do not use bevacizumab for recurrent glioblastoma | 1.7% (1) | 60 |
| Bevacizumab monotherapy | 46.7% (28) | |||
| In combination with a nitrosourea (lomustine or carmustine) | 36.7% (22) | |||
| In combination with temozolomide | 5% (3) | |||
| In combination with irinotecan | 1.7% (1) | |||
| In combination with carboplatin | 3.3% (2) | |||
| In combination with radiation | 1.7% (1) | |||
| In combination with Novo TTF | 3.3% (2) | |||
| 10 | How valuable is bevacizumab overall in the neuro-oncology practice? | Very valuable | 51.7% (31) | 60 |
| Somewhat valuable | 48.3% (29) | |||
| Not valuable at all | 0% (0) |